Telomere Biology of Pediatric Cancer

REFERENCES

• Hanahan D., Weinberg R. A. The hallmarks of cancer. Cell 2000; 100(1)57–70
   PubMed Web of Science ®Google Scholar
• de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 2005; 19(18)2100–2110
   PubMed Web of Science ®Google Scholar
• Griffith J. D., Comeau L., Rosenfield S., Stansel R. M., Bianchi A., Moss H., de Lange T. Mammalian telomeres end in a large duplex loop. Cell 1999; 97: 503–514
   PubMed Web of Science ®Google Scholar
• Smogorzewska A., Karlseder J., Holtgreve-Grez H., Jauch A., de Lange T. DNA ligase IV-dependent NHEJ of deprotected mammalian telomeres in G1 and G2. Curr. Biol. 2002; 12(19)1635–1644
   PubMed Web of Science ®Google Scholar
• Takai H., Smogorzewska A., de Lange T. DNA damage foci at dysfunctional telomeres. Curr. Biol. 2003; 13(17)1549–1556
   PubMed Web of Science ®Google Scholar
• d'Adda di Fagagna F., Reaper P. M., Clay-Farrace L., Fiegler H., Carr P., von Zglinicki T., Saretzki G., Carter N. P., Jackson S. P. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003; 426(6963)194–198
   PubMed Web of Science ®Google Scholar
• Bakkenist C. J., Drissi R., Wu J., Kastan M. B., Dome J. S. Disappearance of the telomere dysfunction-induced stress response in fully senescent cells. Cancer Res. 2004; 64(11)3748–3752
   PubMed Web of Science ®Google Scholar
• Harley C. B. Telomere loss: mitotic clock or genetic time bomb. Mutat. Res. 1991; 256: 271–282
   PubMed Web of Science ®Google Scholar
• Hara E., Tsurui H., Shinozaki A., Nakada S., Oda K. Cooperative effect of antisense-Rb and antisense-p53 oligomers on the extension of life span in human diploid fibroblasts, TIG-1. Biochem. Biophys. Res. Commun. 1991; 179(1)528–534
   PubMed Web of Science ®Google Scholar
• Shay J. W., Pereira-Smith O. M., Wright W. E. A role for both RB and p53 in the regulation of human cellular senescence. Exp. Cell Res. 1991; 196(1)33–39
   PubMed Web of Science ®Google Scholar
• Shay J. W., Wright W. E., Brasiskyte D., Van Der Haegen B. A. E6 of human papillomavirus type 16 can overcome the M1 stage of immortalization in human mammary epithelial cells but not in human fibroblasts. Oncogene 1993; 8(6)1407–1413
   PubMed Web of Science ®Google Scholar
• Bodnar A. G., Ouellette M., Frolkis M., Holt S. E., Chiu C. P., et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279(5349)349–352
   PubMed Web of Science ®Google Scholar
• Vaziri H., Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr. Biol. 1998; 8(5)279–282
   PubMed Web of Science ®Google Scholar
• Counter C. M., Meyerson M., Eaton E. N., Ellisen L. W., Caddle S. D., Haber D. A., Weinberg R. A. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene 1998; 16(9)1217–1222
   PubMed Web of Science ®Google Scholar
• Nakamura T. M., Morin G. B., Chapman K. B., Weinrich S. L., Andrews W. H., Lingner J., Harley C. B., Cech T. R. Telomerase catalytic subunit homologs from fission yeast and human [see comments]. Science 1997; 277(5328)955–959
   PubMed Web of Science ®Google Scholar
• Meyerson M., Counter C. M., Eaton E. N., Ellisen L. W., Steiner P., et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997; 90(4)785–795
   PubMed Web of Science ®Google Scholar
• Feng J., Funk W. D., Wang S. S., Weinrich S. L., Avilion A. A., et al. The RNA component of human telomerase. Science 1995; 269(5228)1236–1241
   PubMed Web of Science ®Google Scholar
• Avilion A. A., Piatyszek M. A., Gupta J., Shay J. W., Bacchetti S., Greider C. W. Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res. 1996; 56(3)645–650
   PubMed Web of Science ®Google Scholar
• Takakura M., Kyo S., Kanaya T., Tanaka M., Inoue M. Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res. 1998; 58(7)1558–1561
   PubMed Web of Science ®Google Scholar
• Blasco M. A., Rizen M., Greider C. W., Hanahan D. Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis. Nat. Genet. 1996; 12(2)200–204
   PubMed Web of Science ®Google Scholar
• Soder A. I., Hoare S. F., Muir S., Going J. J., Parkinson E. K., Keith W. N. Amplification, increased dosage and in situ expression of the telomerase RNA gene in human cancer. Oncogene 1997; 14(9)1013–1021
   PubMed Web of Science ®Google Scholar
• Yashima K., Maitra A., Timmons C. F., Rogers B. B., Pinar H., Shay J. W., Gazdar A. F. Expression of the RNA component of telomerase in Wilms tumor and nephrogenic rest recapitulates renal embryogenesis. Hum. Pathol. 1998; 29(5)536–542
   PubMed Web of Science ®Google Scholar
• Yi X., Tesmer V. M., Savre-Train I., Shay J. W., Wright W. E. Both transcriptional and posttranscriptional mechanisms regulate human telomerase template RNA levels. Mol. Cell Biol. 1999; 19: 3989–3997
   PubMed Web of Science ®Google Scholar
• Guilleret I., Yan P., Guillou L., Braunschweig R., Coindre J. M., Benhattar J. The human telomerase RNA gene (hTERC) is regulated during carcinogenesis but is not dependent on DNA methylation. Carcinogenesis 2002; 23(12)2025–2030
   PubMed Web of Science ®Google Scholar
• Aisner D. L., Wright W. E., Shay J. W. Telomerase regulation: not just flipping the switch. Curr. Opin. Genet. Dev. 2002; 12(1)80–85
   PubMed Web of Science ®Google Scholar
• Kim N. W., Piatyszek M. A., Prowse K. R., Harley C. B., et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266(5193)2011–2015
   PubMed Web of Science ®Google Scholar
• Shay J. W., Bacchetti S. A survey of telomerase activity in human cancer. [Review] [51 refs]. Eur. J. Cancer 1997; 33(5)787–791
   PubMed Web of Science ®Google Scholar
• Bryan T. M., Englezou A., Gupta J., Bacchetti S., Reddel R. R. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J. 1995; 14(17)4240–4248
   PubMed Web of Science ®Google Scholar
• Bryan T. M., Englezou A., Dallapozza L., Dunham M. A., Reddel R. R. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat. Med. 1997; 3(11)1271–1274
   PubMed Web of Science ®Google Scholar
• Hakin-Smith V., Jellinek D. A., Levy D., Carroll T., Teo M., et al. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 2003; 361(9360)836–838
   PubMed Web of Science ®Google Scholar
• Mehle C., Piatyszek M. A., Ljungberg B., Shay J. W., Roos G. Telomerase activity in human renal cell carcinoma. Oncogene 1996; 13(1)161–166
   PubMed Web of Science ®Google Scholar
• Lundblad V., Blackburn E. H. An alternative pathway for yeast telomere maintenance rescues est1-senescence. Cell 1993; 73(2)347–360
   PubMed Web of Science ®Google Scholar
• Teng S. C., Zakian V. A. Telomere-telomere recombination is an efficient bypass pathway for telomere maintenance in Saccharomyces cerevisiae. Mol. Cell Biol. 1999; 19(12)8083–8093
   PubMed Web of Science ®Google Scholar
• Murnane J. P., Sabatier L., Marder B. A., Morgan W. F. Telomere dynamics in an immortal human cell line. EMBO J. 1994; 13(20)4953–4962
   PubMed Web of Science ®Google Scholar
• Dunham M. A., Neumann A. A., Fasching C. L., Reddel R. R. Telomere maintenance by recombination in human cells. Nat. Genet. 2000; 26(4)447–450
   PubMed Web of Science ®Google Scholar
• Bechter O. E., Zou Y., Shay J. W., Wright W. E. Homologous recombination in human telomerase-positive and ALT cells occurs with the same frequency. EMBO Rep. 2003; 4(12)1138–1143
   PubMed Web of Science ®Google Scholar
• Piatyszek M. A., Kim N. W., Weinrich S. L., Hiyama K., Hiyama E., Wright W. E., Shay J. W. Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP). Methods Cell Sci. 1995; 17: 1–15
   Google Scholar
• Dome J. S., Bockhold C. A., Li S. M., Baker S. D., Green D. M., Perlman E. J., Hill D. A., Breslow N. E. High telomerase RNA expression level is an adverse prognostic factor for favorable-histology Wilms' tumor. J. Clin. Oncol. 2005; 23(36)9138–9145
   PubMed Web of Science ®Google Scholar
• Poremba C., Scheel C., Hero B., Christiansen H., Schaefer K. L., et al. Telomerase activity and telomerase subunits gene expression patterns in neuroblastoma: a molecular and immunohistochemical study establishing prognostic tools for fresh-frozen and paraffin-embedded tissues. J. Clin. Oncol. 2000; 18(13)2582–2592
   PubMed Web of Science ®Google Scholar
• Poremba C., Heine B., Diallo R., Heinecke A., Wai D., et al. Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. J. Pathol. 2002; 198(2)181–189
   PubMed Web of Science ®Google Scholar
• Yeager T. R., Neumann A. A., Englezou A., Huschtscha L. I., Noble J. R., Reddel R. R. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res. 1999; 59(17)4175–4179
   PubMed Web of Science ®Google Scholar
• Wu G., Jiang X., Lee W. H., Chen P. L. Assembly of functional ALT-associated promyelocytic leukemia bodies requires Nijmegen Breakage Syndrome 1. Cancer Res. 2003; 63(10)2589–2595
   PubMed Web of Science ®Google Scholar
• Montgomery E., Argani P., Hicks J. L., DeMarzo A. M., Meeker A. K. Telomere lengths of translocation-associated and nontranslocation-associated sarcomas differ dramatically. Am. J. Pathol. 2004; 164(5)1523–1529
   PubMed Web of Science ®Google Scholar
• Henson J. D., Hannay J. A., McCarthy S. W., Royds J. A., Yeager T. R., et al. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin. Cancer Res. 2005; 11(1)217–225
   PubMed Web of Science ®Google Scholar
• Polychronopoulou S., Koutroumba P. Telomere length and telomerase activity: variations with advancing age and potential role in childhood malignancies. J. Pediatr. Hematol. Oncol. 2004; 26(6)342–350
   PubMed Web of Science ®Google Scholar
• Counter C. M., Gupta J., Harley C. B., Leber B., Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 1995; 85(9)2315–2320
   PubMed Web of Science ®Google Scholar
• Hiyama K., Hirai Y., Kyoizumi S., Akiyama M., Hiyama E., Piatyszek M. A., Shay J. W., Ishioka S., Yamakido M. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J. Immunol. 1995; 155(8)3711–3715
   PubMed Web of Science ®Google Scholar
• Chiu C. P., Dragowska W., Kim N. W., Vaziri H., Yui J., Thomas T. E., Harley C. B., Lansdorp P. M. Differential expression of telomerase activity in hematopoietic progenitors from adult human bone marrow. Stem Cells 1996; 14(2)239–248
   PubMed Web of Science ®Google Scholar
• Ohyashiki J. H., Sashida G., Tauchi T., Ohyashiki K. Telomeres and telomerase in hematologic neoplasia. Oncogene 2002; 21(4)680–687
   PubMed Web of Science ®Google Scholar
• Hastie N. D., Dempster M., Dunlop M. G., Thompson A. M., Green D. K., Allshire R. C. Telomere reduction in human colorectal carcinoma and with ageing. Nature 1990; 346: 866–868
   PubMed Web of Science ®Google Scholar
• Vaziri H., Schachter F., Uchida I., Wei L., Zhu X., Effros R., Cohen D., Harley C. B. Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes. Am. J. Hum. Genet. 1993; 52: 661–667
   PubMed Web of Science ®Google Scholar
• Hodes R. J., Hathcock K. S., Weng N. P. Telomeres in T and B cells. Nat. Rev. Immunol. 2002; 2(9)699–706
   PubMed Web of Science ®Google Scholar
• Ohyashiki J. H., Ohyashiki K., Iwama H., Hayashi S., Toyama K., Shay J. W. Clinical implications of telomerase activity levels in acute leukemia. Clin. Cancer Res. 1997; 3(4)619–625
   PubMed Web of Science ®Google Scholar
• Engelhardt M., Ozkaynak M. F., Drullinsky P., Sandoval C., Tugal O., Jayabose S., Moore M. S. Telomerase activity and telomere length in pediatric patients with malignancies undergoing chemotherapy. Leukemia 1998; 12(1)13–24
   PubMed Web of Science ®Google Scholar
• Malaska J., Sklenickova M., Krejci K., Fajkusova L., Bajer M., Hrstkova H., Fajkus J. Telomerase activity and expression and telomere analysis in situ in the course of treatment of childhood leukemias. Blood Cells Mol. Dis. 2000; 26(5)534–539
   PubMed Web of Science ®Google Scholar
• Cogulu O., Kosova B., Karaca E., Gunduz C., Ozkinay F., et al. Evaluation of Telomerase mRNA (hTERT) in Childhood Acute Leukemia. Leuk. Lymphoma 2004; 45(12)2477–2480
   PubMed Web of Science ®Google Scholar
• Verstovsek S., Manshouri T., Smith F. O., Giles F. J., Cortes J., et al. Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia. Cancer 2003; 97(9)2212–2217
   PubMed Web of Science ®Google Scholar
• Huh H. J., Huh J. W., Yoo E. S., Seong C. M., Lee M., Hong K. S., Chung W. S. HTERT mRNA levels by real-time RT-PCR in acute myelogenous leukemia. Am. J. Hematol. 2005; 79(4)267–273
   PubMed Web of Science ®Google Scholar
• Adamson D. J., King D. J., Haites N. E. Significant telomere shortening in childhood leukemia. Cancer Genet Cytogenet. 1992; 61(2)204–206
   PubMed Web of Science ®Google Scholar
• Franco S., Ozkaynak M. F., Sandoval C., Tugal O., Jayabose S., Engelhardt M., Moore M. A. Telomere dynamics in childhood leukemia and solid tumors: a follow-up study. Leukemia 2003; 17(2)401–410
   PubMed Web of Science ®Google Scholar
• Hiyama E., Hiyama K., Yokoyama T., Matsuura Y., Piatyszek M. A., Shay J. W. Correlating telomerase activity levels with human neuroblastoma outcomes [see comments]. Nat. Med. 1995; 1(3)249–255
   PubMed Web of Science ®Google Scholar
• Brinkschmidt C., Poremba C., Christiansen H., Simon R., Schafer K. L., et al. Comparative genomic hybridation and telomerase activity analysis identify two biologically different groups of 4S neuroblastomas. Br. J. Cancer. 1998; 77(12)2223–2229
   PubMed Web of Science ®Google Scholar
• Krams M., Hero B., Berthold F., Parwaresch R., Harms D., Rudolph P. Full-length telomerase reverse transcriptase messenger RNA is an independent prognostic factor in neuroblastoma. Am. J. Pathol. 2003; 162(3)1019–1026
   PubMed Web of Science ®Google Scholar
• Poremba C., Hero B., Heine B., Scheel C., Schaefer K. L., Christiansen H., et al. Telomerase is a strong indicator for assessing the proneness to progression in neuroblastomas. Med. Pediatr. Oncol. 2000; 35(6)651–655
   PubMedGoogle Scholar
• Choi L. M., Kim N. W., Zuo J. J., Gerbing R., Stram D., et al. Telomerase activity by TRAP assay and telomerase RNA (hTR) expression are predictive of outcome in neuroblastoma. Med. Pediatr. Oncol. 2000; 35(6)647–650
   PubMedGoogle Scholar
• Krams M., Claviez A., Heidorn K., Krupp G., Parwaresch R., Harms D., Rudolph P. Regulation of telomerase activity by alternate splicing of human telomerase reverse transcriptase mRNA in a subset of neuroblastomas. Am. J. Pathol. 2001; 159(5)1925–1932
   PubMed Web of Science ®Google Scholar
• Hiyama E., Hiyama K., Nishiyama M., Reynolds C. P., Shay J. W., Yokoyama T. Differential gene expression profiles between neuroblastomas with high telomerase activity and low telomerase activity. J. Pediatr. Surg. 2003; 38(12)1730–1734
   PubMed Web of Science ®Google Scholar
• Hiyama E., Hiyama K., Yokoyama T., Ichikawa T., Matsuura Y. Length of telomeric repeats in neuroblastoma: correlation with prognosis and other biological characteristics. Jpn. J. Cancer Res. 1992; 83(2)159–164
   PubMedGoogle Scholar
• Dome J. S., Chung S., Bergemann T., Umbricht C. B., Saji M., et al. High telomerase reverse transcriptase (hTERT) messenger RNA level correlates with tumor recurrence in patients with favorable histology Wilms' tumor. Cancer Res. 1999; 59(17)4301–4307
   PubMed Web of Science ®Google Scholar
• Hiyama E., Yamaoka H., Matsunaga T., Hayashi Y., Ando H., Suita S., et al. High expression of telomerase is an independent prognostic indicator of poor outcome in hepatoblastoma. Br. J. Cancer. 2004; 91(5)972–979
   PubMed Web of Science ®Google Scholar
• Gupta J., Han L. P., Wang P., Gallie B. L., Bacchetti S. Development of retinoblastoma in the absence of telomerase activity. J. Natl. Cancer Inst. 1996; 88(16)1152–1157
   PubMed Web of Science ®Google Scholar
• Neumann A. A., Reddel R. R. Telomere maintenance and cancer—look, no telomerase. Nat. Rev. Cancer. 2002; 2(11)879–884
   PubMed Web of Science ®Google Scholar
• Ulaner G. A., Huang H. Y., Otero J., Zhao Z., Ben Porat L., et al. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res. 2003; 63(8)1759–1763
   PubMed Web of Science ®Google Scholar
• Aue G., Muralidhar B., Schwartz H. S., Butler M. G. Telomerase activity in skeletal sarcomas. Ann. Surg. Oncol. 1998; 5(7)627–634
   PubMed Web of Science ®Google Scholar
• Sangiorgi L., Gobbi G. A., Lucarelli E., Sartorio S. M., Mordenti M., et al. Presence of telomerase activity in different musculoskeletal tumor histotypes and correlation with aggressiveness. Int. J. Cancer. 2001; 95(3)156–161
   PubMed Web of Science ®Google Scholar
• Scheel C., Schaefer K. L., Jauch A., Keller M., Wai D., et al. Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas. Oncogene. 2001; 20(29)3835–3844
   PubMed Web of Science ®Google Scholar
• Kido A., Schneider-Stock R., Hauptmann K., Roessner A. Telomerase activity in juxtacortical and conventional high-grade osteosarcomas: correlation with grade, proliferative activity and clinical response to chemotherapy. Cancer Lett. 2003; 196(1)109–115
   PubMed Web of Science ®Google Scholar
• Sanders R. P., Drissi R., Billups C. A., Daw N. C., Valentine M. B., Dome J. S. Telomerase expression predicts unfavorable outcome in osteosarcoma. J. Clin. Oncol. 2004; 22(18)3790–3797
   PubMed Web of Science ®Google Scholar
• Sotillo-Pineiro E., Sierrasesumaga L., Patino-Garcia A. Telomerase activity and telomere length in primary and metastatic tumors from pediatric bone cancer patients. Pediatr. Res. 2003
   PubMed Web of Science ®Google Scholar
• Ohali A., Avigad S., Cohen I. J., Meller I., Kollender Y., et al. Association between telomerase activity and outcome in patients with nonmetastatic Ewing family of tumors. J. Clin. Oncol. 2003; 21(20)3836–3843
   PubMed Web of Science ®Google Scholar
• Ulaner G. A., Hoffman A. R., Otero J., Huang H. Y., Zhao Z., et al. Divergent patterns of telomere maintenance mechanisms among human sarcomas: Sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas. Genes Chromosomes Cancer. 2004; 41(2)155–162
   PubMed Web of Science ®Google Scholar
• Yan P., Benhattar J., Coindre J. M., Guillou L. Telomerase activity and hTERT mRNA expression can be heterogeneous and does not correlate with telomere length in soft tissue sarcomas. Int. J. Cancer. 2002; 98(6)851–856
   PubMed Web of Science ®Google Scholar
• Miyoshi Y., Tsukinoki K., Imaizumi T., Yamada Y., Ishizaki T., et al. Telomerase activity in oral cancer. Oral Oncol. 1999; 35(3)283–289
   PubMed Web of Science ®Google Scholar
• Yoo J., Robinson R. A. Expression of telomerase activity and telomerase RNA in human soft tissue sarcomas. Arch. Pathol. Lab. Med. 2000; 124(3)393–397
   PubMed Web of Science ®Google Scholar
• Schneider-Stock R., Boltze C., Jager V., Epplen J., Landt O., Peters B., Rys J., Roessner A. Elevated telomerase activity, c-MYC-, and hTERT mRNA expression: association with tumour progression in malignant lipomatous tumours. J. Pathol. 2003; 199(4)517–525
   PubMed Web of Science ®Google Scholar
• Hiraga S., Ohnishi T., Izumoto S., Miyahara E., Kanemura Y., Matsumura H., Arita N. Telomerase activity and alterations in telomere length in human brain tumors. Cancer Res. 1998; 58(10)2117–2125
   PubMed Web of Science ®Google Scholar
• Didiano D., Shalaby T., Lang D., Grotzer M. A. Telomere maintenance in childhood primitive neuroectodermal brain tumors. Neuro-Oncol. 2004; 6(1)1–8
   PubMed Web of Science ®Google Scholar
• Fan X., Wang Y., Kratz J., Brat D. J., Robitaille Y., Moghrabi A., et al. GhTERT gene amplification and increased mRNA expression in central nervous system embryonal tumors. Am. J. Pathol. 2003; 162(6)1763–1769
   PubMed Web of Science ®Google Scholar
• Chong E. Y., Lam P. Y., Poon W. S., Ng H. K. Telomerase expression in gliomas including the nonastrocytic tumors. Hum. Pathol. 1998; 29(6)599–603
   PubMed Web of Science ®Google Scholar
• Falchetti M. L., Larocca L. M., Pallini R. Telomerase in brain tumors. Childs Nerv. Syst. 2002; 18(3-4)112–117
   PubMed Web of Science ®Google Scholar
• Tabori U., Vukovic B., Zielenska M., Hawkins C., Braude I., et al. The role of telomere maintenance in the spontaneous growth arrest of pediatric low grade gliomas. Neoplasia 2006; 8(2)136–142
   PubMed Web of Science ®Google Scholar
• Fukushima T., Yoshino A., Katayama Y., Watanabe T., Kusama K., Moro I. Prediction of clinical course of diffusely infiltrating astrocytomas from telomerase expression and quantitated activity level. Cancer Lett. 2002; 187(1–2)191
   PubMed Web of Science ®Google Scholar
• Langford L. A., Piatyszek M. A., Xu R., Schold S. C.J., Shay J. W. Telomerase activity in human brain tumours. Lancet 1995; 346(8985)1267–1268
   PubMed Web of Science ®Google Scholar
• Morii K., Tanaka R., Onda K., Tsumanuma I., Yoshimura J. Expression of telomerase RNA, telomerase activity, and telomere length in human gliomas. Biochem. Biophys. Res. Commun. 1997; 239(3)830–834
   PubMed Web of Science ®Google Scholar
• Tchirkov A., Rolhion C., Kemeny J. L., Irthum B., Puget S., et al. Clinical implications of quantitative real-time RT-PCR analysis of hTERT gene expression in human gliomas. Br. J. Cancer. 2003; 88(4)516–520
   PubMed Web of Science ®Google Scholar
• Alonso M. M., Fueyo J., Shay J. W., Aldape K. D., Jiang H., et al. Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance. J. Natl. Cancer Inst. 2005; 97(21)1589–1600
   PubMed Web of Science ®Google Scholar
• Tabori U., Ma J., Carter M., Zielenska M., Rutka J., et al. HTERT expression predicts progression and survival in pediatric intracranial ependymoma. J. Clin. Oncol. 2006; 24(10)1522–1528
   PubMed Web of Science ®Google Scholar
• Marusic L., Anton M., Tidy A., Wang P., Villeponteau B., Bacchetti S. Reprogramming of telomerase by expression of mutant telomerase RNA template in human cells leads to altered telomeres that correlate with reduced cell viability. Mol. Cell Biol. 1997; 17(11)6394–6401
   PubMed Web of Science ®Google Scholar
• Hahn W. C., Stewart S. A., Brooks M. W., York S. G., Eaton E., et al. Inhibition of telomerase limits the growth of human cancer cells. Nat. Med. 1999; 5: 1164–1170
   PubMed Web of Science ®Google Scholar
• Zhang X., Mar V., Zhou W., Harrington L., Robinson M. O. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev. 1999; 13: 2388–2399
   PubMed Web of Science ®Google Scholar
• Nosrati M., Li S., Bagheri S., Ginzinger D., Blackburn E. H., Debs R. J., Kashani-Sabet M. Antitumor activity of systemically delivered ribozymes targeting murine telomerase RNA. Clin. Cancer Res. 2004; 10(15)4983–4990
   PubMed Web of Science ®Google Scholar
• Li S., Rosenberg J. E., Donjacour A. A., Botchkina I. L., Hom Y. K., Cunha G. R., Blackburn E. H. Rapid inhibition of cancer cell growth induced by lentiviral delivery and expression of mutant-template telomerase RNA and anti-telomerase short-interfering RNA. Cancer Res. 2004; 64(14)4833–4840
   PubMed Web of Science ®Google Scholar
• Shay J. W., Wright W. E. Telomerase: a target for cancer therapeutics. Cancer Cell 2002; 2(4)257–265
   PubMed Web of Science ®Google Scholar
• Corey D. R. Telomerase inhibition, oligonucleotides, and clinical trials. Oncogene 2002; 21(4)631–637
   PubMed Web of Science ®Google Scholar
• Kelland L. R. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics—current status and future prospects. Eur. J. Cancer. 2005; 41(7)971–979
   PubMed Web of Science ®Google Scholar
• Herbert B. S., Pongracz K., Shay J. W., Gryaznov S. M. Oligonucleotide N3′– > P5′ phosphoramidates as efficient telomerase inhibitors. Oncogene 2002; 21(4)638–642
   PubMed Web of Science ®Google Scholar
• Herbert B. S., Gellert G. C., Hochreiter A., Pongracz K., Wright W. E., et al. Lipid modification of GRN163, an N3′– > P5′ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 2005; 24(33)5262–5268
   PubMed Web of Science ®Google Scholar
• Gellert G. C., Dikmen Z. G., Wright W. E., Gryaznov S., Shay J. W. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res. Treat. 2005; 1–9
   Google Scholar
• Dikmen Z. G., Gellert G. C., Jackson S., Gryaznov S., Tressler R., et al. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res. 2005; 65(17)7866–7873
   PubMed Web of Science ®Google Scholar
• Damm K., Hemmann U., Garin-Chesa P., Hauel N., Kauffmann I., et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J. 2001; 20(24)6958–6968
   PubMed Web of Science ®Google Scholar
• Pascolo E., Wenz C., Lingner J., Hauel N., Priepke H., et al. Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J. Biol. Chem. 2002; 277(18)15566–15572
   PubMed Web of Science ®Google Scholar
• Ward R. J., Autexier C. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment. Mol. Pharmacol. 2005; 68(3)779–786
   PubMed Web of Science ®Google Scholar
• El-Daly H., Kull M., Zimmermann S., Pantic M., Waller C. F., Martens U. M. Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood 2005; 105(4)1742–1749
   PubMed Web of Science ®Google Scholar
• Grand C. L., Han H., Munoz R. M., Weitman S., Von Hoff D. D., Hurley L. H., Bearss D. J. The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol. Cancer Ther. 2002; 1(8)565–573
   PubMed Web of Science ®Google Scholar
• Burger A. M., Dai F., Schultes C. M., Reszka A. P., Moore M. J., Double J. A., Neidle S. The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. Cancer Res. 2005; 65(4)1489–1496
   PubMed Web of Science ®Google Scholar
• Cookson J. C., Dai F., Smith V., Heald R. A., Laughton C. A., Stevens M. F., Burger A. M. Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4) in vitro: activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents. Mol. Pharmacol. 2005; 68(6)1551–1558
   PubMed Web of Science ®Google Scholar
• Binz N., Shalaby T., Rivera P., Shin-Ya K., Grotzer M. A. Telomerase inhibition, telomere shortening, cell growth suppression and induction of apoptosis by telomestatin in childhood neuroblastoma cells. Eur. J. Cancer. 2005; 41(18)2873–2881
   PubMed Web of Science ®Google Scholar
• Gowan S. M., Heald R., Stevens M. F., Kelland L. R. Potent inhibition of telomerase by small-molecule pentacyclic acridines capable of interacting with g-quadruplexes. Mol. Pharmacol. 2001; 60(5)981–988
   PubMed Web of Science ®Google Scholar
• Pennarun G., Granotier C., Gauthier L. R., Gomez D., Hoffschir F., et al. Apoptosis related to telomere instability and cell cycle alterations in human glioma cells treated by new highly selective G-quadruplex ligands. Oncogene 2005; 24(18)2917–2928
   PubMed Web of Science ®Google Scholar
• Tahara H., Shin-Ya K., Seimiya H., Yamada H., Tsuruo T., Ide T. G-quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 3′ telomeric overhang in cancer cells. Oncogene 2005
   Web of Science ®Google Scholar
• Rha S. Y., Izbicka E., Lawrence R., Davidson K., Sun D., et al. Effect of telomere and telomerase interactive agents on human tumor and normal cell lines. Clin. Cancer Res. 2000; 6(3)987–993
   PubMed Web of Science ®Google Scholar
• Vonderheide R. H. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 2002; 21(4)674–679
   PubMed Web of Science ®Google Scholar
• Kim E., Kim J. H., Shin H. Y., Lee H., Yang J. M., et al. Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum. Gene Ther. 2003; 14(15)1415–1428
   PubMed Web of Science ®Google Scholar
• Huang Q., Zhang X., Wang H., Yan B., Kirkpatrick J., Dewhrist M. W., Li C. Y. A novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells. Clin. Cancer Res. 2004; 10(4)1439–1445
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani R., Ohana P., Matouk I., Ayesh S., Ayesh B., et al. Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. Mol. Ther. 2000; 2(6)539–544
   PubMed Web of Science ®Google Scholar
• Koga S., Hirohata S., Kondo Y., Komata T., Takakura M., Inoue M., Kyo S., Kondo S. A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Hum. Gene Ther. 2000; 11(10)1397–1406
   PubMed Web of Science ®Google Scholar
• Koga S., Hirohata S., Kondo Y., Komata T., Takakura M., et al. FADD gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter to restrict induction of apoptosis to tumors in vitro and in vivo. Anticancer Res. 2001; 21(3B)1937–1943
   PubMed Web of Science ®Google Scholar
• Gu J., Kagawa S., Takakura M., Kyo S., Inoue M., Roth J. A., Fang B. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res. 2000; 60(19)5359–5364
   PubMed Web of Science ®Google Scholar
• Majumdar A. S., Hughes D. E., Lichtsteiner S. P., Wang Z., Lebkowski J. S., Vasserot A. P. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Ther. 2001; 8(7)568–578
   PubMed Web of Science ®Google Scholar
• Plumb J. A., Bilsland A., Kakani R., Zhao J., Glasspool R. M., et al. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene 2001; 20(53)7797–7803
   PubMed Web of Science ®Google Scholar